VYNE Therapeutics (VYNE) Non-Current Assets (2016 - 2026)
VYNE Therapeutics (VYNE) posted Non-Current Assets of $84000.0 for Q1 2026, down 44.0% on a QoQ basis from $150000.0 in Q4 2025, and down 94.44% year-over-year from $1.5 million in Q1 2025.
VYNE Therapeutics (VYNE) Non-Current Assets (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Non-Current Assets history runs 11 years deep, the most recent figure standing at $84000.0 for Q1 2026.
- Quarterly Non-Current Assets fell 94.44% year-over-year to $84000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84000.0 (down 94.44% YoY) and the FY2025 annual result came in at $150000.0, down 93.92% from the prior year.
- Non-Current Assets was $84000.0 for Q1 2026 at VYNE Therapeutics, down from $150000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.7 million in Q1 2022 and bottomed at $84000.0 in Q1 2026.
- A 5-year average of $2.0 million and a median of $2.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets jumped 51.65% — and 2026, when it sank 94.44%.
- VYNE Therapeutics' Non-Current Assets stood at $2.5 million in 2022, then slumped by 30.65% to $1.7 million in 2023, then soared by 43.32% to $2.5 million in 2024, then sank by 93.92% to $150000.0 in 2025, then plunged by 44.0% to $84000.0 in 2026.
- Business Quant data shows VYNE's Non-Current Assets at $84000.0 in Q1 2026, $150000.0 in Q4 2025, and $375000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 285.82 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 84,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 150,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | 2.48 Mn |
| Sep 30, 2022 | 2.86 Mn |
| Jun 30, 2022 | 3.27 Mn |
| Mar 31, 2022 | 3.67 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 5.19 Mn |
| Jun 30, 2021 | 5.56 Mn |
| Mar 31, 2021 | 6.05 Mn |